Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT04978948
Recruiting Observational

Study of STIM1 Membrane Expression

NCT04978948 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Observational
Started
2021-05-11
Last updated
2026-06-26

Condition(s) studied

Autoimmune Diseases

Study summary

The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM.

This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of one of the autoimmune diseases Exclusion Criteria: * Treatment with rituximab in the previous 12 months

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
CHRU de Brest - Service de rhumatologie Brest Brest Recruiting
Centre Hospitalier des Pays de Morlaix Morlaix Brittany Region Recruiting
Centre Hospitalier de Quimper Quimper Brittany Region Recruiting
CHU de Martinique Fort-de-France Martinique Recruiting

More University Hospital, Brest trials in France

Droplet Digital PCR and PCR-free BIOSensors for the Detection of Resistance-associated SNPs in Pneumocystis Jirovecii Active, not recruiting
Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis Active, not recruiting
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP) Recruiting
Anatomical Assessment of Orbital Contents on Imaging (EACOI) Recruiting
Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation Recruiting

Other trials for the same condition

The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. Recruiting
Natural History of Type 1 Interferonopathies: Insights From a European Cohort Recruiting
Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions Recruiting
Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases Starting soon
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04978948 on ClinicalTrials.gov ↗ ← All trials in France